|
|
Article: Accentia Biopharmaceutical's Revimmune Receives the Frost & Sullivan Multiple Sclerosis Product Innovation of the Year Award.
- Article from:
- Business Wire
- Article date:
- March 13, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that Revimmune[TM], its potential blockbuster therapeutic candidate designed to treat up to 80 autoimmune diseases, has been awarded the Frost & Sullivan 2007 North American Multiple Sclerosis Product Innovation of the Year Award. If approved, Revimmune would be the first product capable of restoring neurological function in patients with relapsing-remitting multiple sclerosis (MS). Accentia intends to file an Investigational New Drug Application (IND), aiming to commence a Phase 3 MS clinical trial this year.
The selection of the Frost & Sullivan Award comes through in-depth ...